Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2012 - 2023)
Tonix Pharmaceuticals Holding (TNXP) posted Other Non-Current Liabilities of $14.6 million for Q4 2023, up 437.59% on a QoQ basis from $2.7 million in Q1 2012.
Powered by 
Analysis
Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2012 - 2023) Analysis & Trends
Tonix Pharmaceuticals Holding has reported Other Non-Current Liabilities for 2 years, with the latest figure at $14.6 million in Q4 2023.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $14.6 million in Q4 2023; TTM through Dec 2023 was $14.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $14.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $14.6 million for Q4 2023 at Tonix Pharmaceuticals Holding, up from $2.7 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $14.6 million in Q4 2023, with the low at $14.6 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | Tonix Pharmaceuticals Holding | 220.65 Mn | 220.65 Mn | 12.84 Mn |